In this study, we examined whether local deferoxamine (DFO) administration can promote angiogenesis and bone repair in steroid-induced osteonecrosis of the femoral head (ONFH). Steroid-induced ONFH was induced in 65 mature male New Zealand white rabbits by methylprednisolone in combination with lipopolysaccharide. Six weeks later, the rabbits received no treatment (model group, N = 15), bilateral core decompression (CD group, N = 20) or CD in combination with local DFO administration (DFO group, N = 20). Six weeks after the surgery, vascularization in the femoral head was evaluated by ink artery infusion angiography and immunohistochemical staining for von Willebrand Factor (vWF). Bone repair was assessed by histologic analysis and micro-computed tomography (micro-CT). Immunohistochemical staining was performed to analyze the expression of vascular endothelial growth factor (VEGF), hypoxia-inducible factor-1α (HIF-1α), bone morphogenetic protein-2 (BMP-2), and osteocalcin (OCN). Ink artery infusion angiography and microvessel analysis by immuohistochemical staining for vWF showed more blood vessels in the DFO group than other groups. The expression of HIF-1α, VEGF, BMP-2, and OCN, indicated by immunohistochemical staining, was higher in the DFO group compared with other groups. Micro-CT scanning results indicated that the DFO group had larger volume of newly formed bone than the CD group. This work indicated that local DFO administration improved angiogenesis and bone repair of early stage ONFH in rabbit model, and it may offer an efficient, economic, and simple therapy for early stage ONFH.
MontMAJonesLCHungerfordDS. Nontraumatic osteonecrosis of the femoral head: ten years later. J Bone Joint Surg Am2006; 88A: 1117–32.
2.
LealiAFettoJHaleJJ. Biostructural augmentation for the treatment of osteonecrosis: rationale, technique, and case example. J South Orthop Assoc2002; 11: 167–71.
3.
MontMAJonesLCEinhornTAHungerfordDSReddiAH. Osteonecrosis of the femoral head – potential treatment with growth and differentiation factors. Clin Orthop Relat Res1998; 355: S314–35.
4.
ChiuKHShenWYKoCKChanKM. Osteonecrosis of the femoral head treated with cementless total hip arthroplasty – a comparison with other diagnoses. J Arthroplasty1997; 12: 683–8.
5.
LiebermanJR. Core decompression for osteonecrosis of the hip. Clin Orthop Relat Res2004; 418: 29–33.
6.
ScullySPAaronRKUrbaniakJR. Survival analysis of hips treated with core decompression or vascularized fibular grafting because of avascular necrosis. J Bone Joint Surg Am1998; 80A: 1270–5.
7.
RiddleRCKhatriRSchipaniEClemensTL. Role of hypoxia-inducible factor-1 alpha in angiogenic-osteogenic coupling. J Mol Med (Berl)2009; 87: 583–90.
8.
AsikainenTMAhmadASchneiderBKHoWBArendMBrennerMGunzlerVWhiteCW. Stimulation of HIF-1 alpha, HIF-2 alpha, and VEGF by prolyl 4-hydroxylase inhibition in human lung endothelial and epithelial cells. Free Radic Biol Med2005; 38: 1002–13.
9.
LiY-XDingS-JXiaoLGuoWZhanQ. Desferoxamine preconditioning protects against cerebral ischemia in rats by inducing expressions of hypoxia inducible factor 1 alpha and erythropoietin. Neurosci Bull2008; 24: 89–95.
10.
HishikawaTOnoSOgawaTTokunagaKSugiuKDateI. Effects of deferoxamine-activated hypoxia-inducible factor-1 on the brainstem after subarachnoid hemorrhage in rats. Neurosurgery2008; 62: 232–40.
11.
ShenXWanCRamaswamyGMavalliMWangYDuvallCLDengLFGuldbergREEberhartAClemensTLGilbertSR. Prolyl hydroxylase inhibitors increase neoangiogenesis and callus formation following femur fracture in mice. J Orthop Res2009; 27: 1298–305.
12.
StewartRGoldsteinJEberhardtAChuGGilbertS. Increasing vascularity to improve healing of a segmental defect of the rat femur. J Orthop Trauma2011; 25: 472–6.
13.
QinLZhangGShengHYeungKWYeungHYChanCWCheungWHGriffithJChiuKHLeungKS. Multiple bioimaging modalities in evaluation of an experimental osteonecrosis induced by a combination of lipopolysaccharide and methylprednisolone. Bone2006; 39: 863–71.
14.
DrescherWFurstMHahneHJHelfensteinAPetersenWHassenpflugJ. Survival analysis of hips treated with flexion osteotomy for femoral head necrosis. J Bone Joint Surg Br2003; 85B: 969–74.
15.
SchipaniEMaesCCarmelietGSemenzaGL. Regulation of osteogenesis–angiogenesis coupling by HIFs and VEGF. J Bone Miner Res2009; 24: 1347–53.
16.
WanCGilbertSRWangYCaoXShenXRamaswamyGJacobsenKAAlaqlZSEberhardtAWGerstenfeldLCEinhornTADengLClemensTL. Activation of the hypoxia-inducible factor-1 alpha pathway accelerates bone regeneration. Proc Natl Acad Sci U S A2008; 105: 686–91.
LiXDJinLCuiQJWangGJBalianG. Steroid effects on osteogenesis through mesenchymal cell gene expression. Osteoporos Int2005; 16: 101–8.
19.
HaradaI. The effects of glucocorticoids on angiogenesis in vitro. Nihon Seikeigeka Gakkai zasshi1992; 66: 763–70.
20.
FerraraN. Molecular and biological properties of vascular endothelial growth factor. J Mol Med (Berl)1999; 77: 527–43.
21.
StreetJBaoMdeGuzmanLBuntingSPealeFVFerraraNSteinmetzHHoeffelJClelandJLDaughertyAvan BruggenNRedmondHPCaranoRAFilvaroffEH. Vascular endothelial growth factor stimulates bone repair by promoting angiogenesis and bone turnover. Proc Natl Acad Sci U S A2002; 99: 9656–61.
22.
KellyBDHackettSFHirotaKOshimaYCaiZQBerg-DixonSRowanAYanZCampochiaroPASemenzaGL. Cell type-specific regulation of angiogenic growth factor gene expression and induction of angiogenesis in nonischemic tissue by a constitutively active form of hypoxia-inducible factor 1. Circ Res2003; 93: 1074–81.
23.
WangYWanCDengLFLiuXMCaoXMGilbertSRBouxseinMLFaugereMCGuldbergREGerstenfeldLCHaaseVHJohnsonRSSchipaniEClemensTL. The hypoxia-inducible factor a pathway couples angiogenesis to osteogenesis during skeletal development. J Clin Invest2007; 117: 1616–26.
24.
ThebaudNBSiadousRBareilleRRemyMDaculsiRAmedeeJBordenaveL. Whatever their differentiation status, human progenitor derived – or mature – endothelial cells induce osteoblastic differentiation of bone marrow stromal cells. J Tissue Eng Regen Med2012; 6: e51–60.
25.
GruberRKandlerBHolzmannPVogele-KadletzMLosertUFischerMBWatzekG. Bone marrow stromal cells can provide a local environment that favors migration and formation of tubular structures of endothelial cells. Tissue Eng2005; 11: 896–903.
26.
PotapovaIAGaudetteGRBrinkPRRobinsonRBRosenMRCohenISDoroninSV. Mesenchymal stem cells support migration, extracellular matrix invasion, proliferation, and survival of endothelial cells in vitro. Stem Cells2007; 25: 1761–8.
27.
RackwitzLEdenLReppenhagenSReichertJCJakobFWallesHPulligOTuanRSRudertMNothU. Stem cell- and growth factor-based regenerative therapies for avascular necrosis of the femoral head. Stem Cell Res Ther2012; 3: 7–7.
28.
LiebermanJRConduahAUristMR. Treatment of osteonecrosis of the femoral head with core decompression and human bone morphogenetic protein. Clin Orthop Relat Res2004; 429: 139–45.
29.
ThurstonGRudgeJSIoffeEZhouHRossLCrollSDGlazerNHolashJMcDonaldDMYancopoulosGD. Angiopoietin-1 protects the adult vasculature against plasma leakage. Nat Med2000; 6: 460–3.
30.
YamakawaMLiuLXDateTBelangerAJVincentKAAkitaGYKuriyamaTChengSHGregoryRJJiangC. Hypoxia-inducible factor-1 mediates activation of cultured vascular endothelial cells by inducing multiple angiogenic factors. Circ Res2003; 93: 664–73.
31.
FuldaSDebatinK-M. HIF-1-regulated glucose metabolism a key to apoptosis resistance?Cell Cycle2007; 6: 790–2.
32.
TsaiCCChenYJYewTLChenLLWangJYChiuCHHungSC. Hypoxia inhibits senescence and maintains mesenchymal stem cell properties through down-regulation of E2A-p21 by HIF-TWIST. Blood2011; 117: 459–69.
33.
HungSCPochampallyRRHsuSCSanchezCChenSCSpeesJProckopDJ. Short-term exposure of multipotent stromal cells to low oxygen increases their expression of CX3CR1 and CXCR4 and their engraftment in vivo. PLoS ONE2007; 2: e416–e416.
34.
UngerEFThompsonAMBlankMJTempleR. Erythropoiesis-stimulating agents – time for a reevaluation. N Engl J Med2010; 362: 189–92.
